Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes.

by Randy Hecht, Yue-Sheng Li, Jeonghoon Sun, Ed Belouski, Michael Hall, Todd Hager, Junming Yie, Wei Wang, Dwight Winters, Stephen Smith, Chris Spahr, Lei-Ting Tam, Zhongnan Shen, Shanaka Stanislaus, Narumol Chinookoswong, Yvonne Lau, Allen Sickmier, Mark Leo Michaels, Thomas Boone, Murielle M Véniant, Jing Xu
Published 2012-01-01